Meeting
2013 Genitourinary Cancers Symposium
Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety and tolerability results.
Authors
Roberto Pili
Roswell Park Cancer Institute, Buffalo, NY
Roberto Pili , Li Shen , Saby George , Hans J. Hammers , Anita Sandecki , Connie Collins , Michael Anthony Carducci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01038778
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 369)
DOI
10.1200/jco.2013.31.6_suppl.369
Abstract #
369
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870).
First Author: Roberto Pili
Poster
2018 ASCO Annual Meeting
Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.
First Author: Toshio Kubo
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips